Sort
16,300 grants matching “fatty liver disease”
ADIPOSE TISSUE MACROPHAGE PHENOTYPE AND FUNCTION
$480,830Anthony W Ferrante · Columbia University Health Sciences · R01 · FY2019 · DK
ADIPOSE TISSUE MACROPHAGE PHENOTYPE AND FUNCTION
$480,830Anthony W Ferrante · Columbia University Health Sciences · R01 · FY2020 · DK
A poly-omic study of the molecular mechanisms underlying maternal diet interventions for offspring obesity and NAFLD
$480,754Linglin Xie · Texas A&M Agrilife Research · R01 · FY2019 · DK
CDU Diversity-promoting Institutions Drug Abuse Research Development Program
$480,725Theodore C Friedman · Charles R. Drew University Of Med & Sci · R24 · FY2016 · DA
Macrophage Functional Response in Hemolytic Complications
$480,712Francesca Vinchi · New York Blood Center · P01 · FY2024 · HL
Tumor Detection and Classification using QUS Technology's Structure Function
$480,630William D. O'Brien · University Of Illinois At Urbana-Champaign · R01 · FY2020 · CA
Effect of sphingomyelin biosynthesis on atherosclerosis
$480,596Xian-Cheng Jiang · Suny Downstate Medical Center · R01 · FY2021 · HL
Effect of sphingomyelin biosynthesis on atherosclerosis
$480,596Xian-Cheng Jiang · Suny Downstate Medical Center · R01 · FY2020 · HL
Regulation of Cellular Cholesterol Homeostasis
$480,383Peter John Espenshade · Johns Hopkins University · R01 · FY2021 · HL
Lipid Aldehyde and Ethanol Induced Liver Damage
$480,084Dennis Petersen · University Of Colorado Denver · R37 · FY2016 · AA
NASH PROJECT
$480,051Case Western Reserve University · U01 · FY2004 · DK
Control of glucose homeostasis through the insulin-independent Isthmin pathway
$480,046Katrin Jennifer Svensson · Stanford University · R01 · FY2022 · DK
G0S2 and lipid metabolism in the regulation of hematopoietic development
$480,000Anna Marie Eiring · Texas Tech University Health Sciences Center At El Paso · R15 · FY2024 · HL
Ubiquitin D as a potential therapeutic target for NASH, HCC and chronic kidney diseases
$480,000Debanjan Dhar · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2024 · DK
Them1 Inhibitors for the Management of Non-Alcoholic Fatty Liver Disease
$479,998David E Cohen · Brigham And Women'S Hospital · R01 · FY2024 · DK
Cross-regulation of Immunometabolism and Circadian Pathways in Obesity Pathophysiology
$479,959Joseph T Bass · Northwestern University At Chicago · R01 · FY2021 · DK
TTC39B in Metabolism
$479,823Alan Richard Tall · Columbia University Health Sciences · R01 · FY2020 · HL
Loss of AGPAT2, insulin resistance, NAFLD and altered adipocyte differentiation
$479,756Jay D Horton · Ut Southwestern Medical Center · P01 · FY2016 · DK
Control of glucose homeostasis through the insulin-independent Isthmin pathway
$479,642Katrin Jennifer Svensson · Stanford University · R01 · FY2021 · DK
Hepatic Steatosis Quantification with Ultrasound
$479,519Shigao Chen · Mayo Clinic Rochester · R01 · FY2024 · DK
Tissue Responses to Metabolic Stress
$479,260Jean E Schaffer · Washington University · R01 · FY2019 · DK
MR Imaging of Non-Alcoholic Fatty Liver Disease
$479,146Claude B Sirlin · University Of California, San Diego · R01 · FY2010 · DK
Comparative Effectiveness of Advanced Diagnostic Imaging for Hepatic Fibrosis
$479,082Jayant A Talwalkar · Mayo Clinic Rochester · RC1 · FY2009 · EB
Novel strategies to resolve metabolic defects in the diabetic heart
$478,956Iain Scott · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · HL
Novel strategies to resolve metabolic defects in the diabetic heart
$478,956Iain Scott · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · HL